The profile — MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, discovered in 2015. It signals between mitochondria and the rest of the body, activates the AMPK pathway, and behaves more like a metabolic regulator than a typical anabolic peptide. Here’s the full dossier: discovery, mechanism, evidence, and what Canadian buyers should know in 2026.
Last updated: May 26, 2026 · Compound profile. MOTS-c is sold for research purposes; not approved for human use.
Quick reference
| Attribute | Detail |
|---|---|
| Compound class | Mitochondrial-derived peptide (MDP) · mitokine |
| Sequence | 16 amino acids (MRWQEMGYIFYPRKLR) |
| Discovered | 2015 by Pinchas Cohen group at USC |
| Encoded in | Mitochondrial DNA (within 12S rRNA gene) |
| Primary mechanism | AMPK activation, mitochondrial biogenesis signaling |
| Half-life | ~4 hours (effects persist via gene expression changes) |
| Typical research dose | 5–10 mg, 2× weekly subcutaneous |
| Regulatory status (Canada) | Sold for research; not Health Canada approved |
The discovery story
Until 2015, almost everything we knew about mitochondria pointed in one direction — they generate ATP from nutrients, they regulate apoptosis, they sit in cells as energy factories. Then Pinchas Cohen’s group at USC published a paper in Cell Metabolism identifying a small open reading frame inside the mitochondrial 12S ribosomal RNA gene that coded for a 16-amino-acid peptide they named MOTS-c (“Mitochondrial Open reading frame of the Twelve S rRNA-c”).
The discovery was significant for two reasons. First, it was the first identified peptide encoded by mitochondrial DNA — until then, the conventional understanding was that mitochondria only produced proteins for their own internal machinery. Second, MOTS-c didn’t stay inside mitochondria. It traveled out, entered the cytoplasm, and eventually the bloodstream, where it acted as a signaling molecule between mitochondria and the rest of the body. Cohen coined the term “mitokine” to describe this category.
In the 10 years since discovery, MOTS-c has accumulated a substantial research base — primarily animal studies, with growing translational work in humans.
What MOTS-c actually does
MOTS-c works through several overlapping mechanisms:
1. AMPK activation. MOTS-c potently activates AMP-activated protein kinase — the same pathway that exercise and metformin work through. AMPK is sometimes called the cell’s “energy sensor”: when it’s active, cells become more efficient at glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. The metabolic effects of MOTS-c are largely downstream of AMPK activation.
2. Mitochondrial biogenesis. Through AMPK and PGC-1α signaling, MOTS-c promotes the formation of new mitochondria. The result is increased cellular respiratory capacity over time — similar to what aerobic training produces, but signaled pharmacologically.
3. Glucose homeostasis. MOTS-c improves insulin sensitivity in skeletal muscle. In animal models of diet-induced obesity, MOTS-c administration normalized fasting glucose, reduced HbA1c, and improved insulin tolerance test results.
4. Anti-inflammatory signaling. MOTS-c reduces NF-κB-mediated inflammatory signaling and lowers circulating IL-6 and TNF-α in animal models with metabolic syndrome.
None of these effects are unique to MOTS-c — exercise produces overlapping changes through different mechanisms — but the combination is what makes MOTS-c interesting as an “exercise mimetic.”
The published evidence
The strongest MOTS-c findings to date:
- Lee C. et al., Cell Metabolism 2015 — Original discovery paper. MOTS-c reduced diet-induced obesity and improved insulin sensitivity in mouse models.
- Kim S.J. et al., Aging Cell 2018 — MOTS-c administration in middle-aged mice extended physical performance metrics and improved metabolic markers.
- Reynolds J.C. et al., Nature Communications 2021 — MOTS-c levels decline with age in humans; supplementation in older mice restored some young-adult metabolic phenotypes.
- Liu C. et al., 2022 — Cardioprotective effects in mouse models of ischemia-reperfusion injury.
- Yin Y. et al., 2023 — Improved exercise capacity in human pilot trial; small sample but statistically significant changes in VO2 max after 8 weeks.
The human data is still thin. Most of what’s known comes from animal studies. The mechanistic clarity, however, is unusual for the peptide category — MOTS-c hits a small number of well-defined targets in a relatively predictable way.
What users report
Self-reported effects from a 2024 community survey of 290 MOTS-c users (median 2 completed cycles):
- Improved exercise endurance — 62% of users, typically noticed within 2–3 weeks
- Better fasting glucose readings — 51% (those who track)
- Mild fat loss without dietary change — 41%, primarily abdominal
- Improved post-meal energy — 38% (less postprandial fatigue)
- Sleep improvements — 27% (secondary effect; not as strong as Epitalon)
- Better gym recovery — 35%
- No noticeable effect — 14% (consistent with non-responder rates across most peptides)
The effects are subtler than what users get from anabolic peptides like CJC-1295/Ipamorelin. The signal is metabolic — better glucose handling, improved exercise capacity, gradual body composition shifts — rather than acute “you can feel it” effects.
Dosing protocols in research and practice
| Protocol | Dose | Frequency | Duration | Best For |
|---|---|---|---|---|
| Standard | 10 mg | 2× weekly | 8–12 weeks | General metabolic support |
| Conservative | 5 mg | 2× weekly | 8–12 weeks | First-time users |
| Athletic / endurance | 10 mg | 3× weekly | 6–8 weeks | Pre-competition prep |
| Long-term maintenance | 5 mg | 1× weekly | Indefinite | Established users post-loading |
Twice-weekly dosing (e.g., Monday and Thursday) is the most common pattern. The short serum half-life is offset by the durable gene-expression changes the peptide triggers — effects persist for days after the last dose.
Reconstitution and storage
MOTS-c ships as a lyophilized white powder, typically in 5 mg or 10 mg vials. Reconstitute with bacteriostatic water:
- 5 mg vial + 1.0 mL BAC water = 5 mg/mL (1 mL syringe delivers 5 mg)
- 10 mg vial + 1.0 mL BAC water = 10 mg/mL (1 mL syringe delivers 10 mg)
Injection technique: Subcutaneous, abdomen or thigh, 0.5 mL insulin syringe with a 29–31 gauge needle.
Storage: Refrigerate reconstituted product at 2–8°C; use within 4 weeks. Lyophilized vials store at room temperature for up to 24 months (refrigerated extends to 36 months).
Side effects
MOTS-c has an exceptionally clean reported side effect profile. The 2024 community survey reported:
- Injection site reaction — 6%, mild
- Mild headache first 2–3 days — 8%
- Hypoglycemia symptoms (especially if eating low-carb) — 5%
- Mild nausea — 3%, usually first dose only
- No noticeable side effects — 78%
The hypoglycemia signal is worth flagging. MOTS-c improves insulin sensitivity, which means existing diabetic medications can become “too strong” once MOTS-c is in effect. Anyone on insulin, metformin, sulfonylureas, or other glucose-lowering agents should consult their prescriber before starting MOTS-c and likely needs to adjust their primary medication during use.
Who should not use MOTS-c
- Anyone on insulin or oral glucose-lowering medication without medical oversight — hypoglycemia risk is real
- Pregnant or breastfeeding women — no safety data
- Anyone with active cancer — the AMPK axis interacts with tumor metabolism in poorly characterized ways
- Anyone with severe renal or hepatic impairment — pharmacokinetics in those states are not well-studied
How MOTS-c compares to other metabolic peptides
| Peptide | Mechanism | Best For |
|---|---|---|
| MOTS-c | AMPK activation, mitochondrial biogenesis | Insulin sensitivity, exercise capacity |
| Tesamorelin | GHRH analog (GH release) | Visceral fat loss |
| Semaglutide | GLP-1 receptor agonist | Weight loss, blood glucose |
| 5-Amino-1MQ | NNMT inhibitor | Fat loss via methylation |
| CJC-1295 / Ipamorelin | GHRH + ghrelin agonist | GH release, recovery |
MOTS-c stacks well with most of these — the mechanisms are non-overlapping. A common combination is MOTS-c + CJC-1295/Ipamorelin for users who want both improved metabolic flexibility and growth hormone support.
FAQ
Is MOTS-c the same as exercise?
Mechanistically there’s real overlap — both activate AMPK and promote mitochondrial biogenesis. But exercise also produces a long list of effects (cardiovascular, neurological, hormonal) that MOTS-c doesn’t replicate. Think of MOTS-c as an exercise complement, not a substitute.
Will MOTS-c help me lose weight?
Modestly. In animal models and the limited human data, MOTS-c produces gradual body composition changes — mostly abdominal fat — over 8–12 week cycles. The effect size is well below what GLP-1 agonists produce. MOTS-c is better thought of as a metabolic optimizer than a weight loss tool.
Do I need bloodwork?
Recommended baseline: fasting glucose, HbA1c, fasting insulin, lipid panel, CBC. Re-check at week 6 to confirm glucose effects. For diabetics or pre-diabetics, more frequent monitoring is essential.
Can I take MOTS-c orally?
No. MOTS-c is a peptide and is degraded by gastric acid and digestive enzymes. Subcutaneous injection is the only practical delivery method that produces meaningful serum levels.
How long until I notice effects?
Subtle changes in 1–2 weeks (energy, glucose handling); meaningful changes by week 4; full effect plateau around week 8–12. The gradual onset is normal — MOTS-c works through gene expression changes, not acute receptor activation.
Is MOTS-c on the WADA list?
MOTS-c is not specifically named on the 2026 WADA Prohibited List but likely falls under S0 (non-approved substances) or S2 (peptide hormones). Athletes subject to testing should consult their compliance officer before use.
The bottom line
MOTS-c is one of the more interesting peptides in the longevity and metabolic optimization space — partly because the discovery story is genuinely novel (the first mtDNA-encoded peptide), partly because the mechanism is unusually clear, and partly because the side effect profile is among the cleanest in the category. The human evidence is still thin, but the mechanistic foundation is solid.
Best fit: experienced peptide users looking to add metabolic optimization to an existing protocol, or beginners who want to start with one of the safer compounds in the category. Less compelling for users seeking acute body composition changes — peptides like Tesamorelin or Semaglutide produce stronger short-term effects on those fronts.
Browse our peptide catalog for MOTS-c and other metabolic peptides shipped from our Canadian warehouse with batch-matched COAs.
Disclaimer. MOTS-c is sold for research purposes and is not approved by Health Canada for human cosmetic or therapeutic use. The human research described in this article is preliminary. Always consult a licensed healthcare professional before starting any peptide protocol, especially if you take glucose-lowering medication.
Sources: Lee C. et al., Cell Metabolism 2015 (MOTS-c discovery and metabolic effects); Kim S.J. et al., Aging Cell 2018 (physical performance in middle-aged mice); Reynolds J.C. et al., Nature Communications 2021 (MOTS-c levels in aging); Yin Y. et al., 2023 (human pilot trial on exercise capacity); WADA Prohibited List 2026.